Newfoundland and Labrador-based biotechnology company Sequence Bio is pleased to announce the addition of Lynn Healey (CPA, CA) to its executive team as Chief Financial Officer. As CFO, Lynn will be instrumental in supporting Sequence Bio’s next phase of growth, bringing world-class expertise to financial, administrative, and human resource operations, including investor relations, and talent acquisition and professional development.
Lynn brings over 25 years of strategic leadership experience to her role at Sequence Bio. Most recently, she was the Chief Investment Officer of the Teachers’ Pension Plan Corporation, the trustee and administrator of the Teachers’ Pension Plan in Newfoundland and Labrador with more than 18,000 members and invested assets of approximately $4 billion. In her role, she was responsible for all facets of the investment and treasury function for the Corporation, and for the development of sustainable, long-term investment strategies for the Plan. Prior to that, Lynn was a Partner with EY (Ernst & Young) in Toronto and St. John’s, providing transaction and assurance advisory services to some of Canada’s largest and fastest-growing companies.
Lynn is a highly active and committed volunteer in the province: in addition to volunteering with the Dr. H. Bliss Murphy Cancer Care Foundation’s Polka Dot Trot, she serves as Director and Treasurer with the Royal St. John’s Regatta Committee, and is a Director with the Chartered Professional Accountants of Newfoundland and Labrador.
“I have been following Sequence Bio since its beginning in 2013, and I’m excited about the work we are doing to benefit the health outcomes of people in our province and beyond. ” said Lynn. "The opportunity to join a rapidly growing Newfoundland and Labrador company with such a meaningful purpose spoke to me, and I’m very proud to count myself among a dedicated team that works hard every day to make a lasting, positive impact.”
Chris Garder, CEO of Sequence Bio said, “Lynn is a highly respected Newfoundlander and Labradorian whose leadership is recognized internationally.” He continued: “Her expertise and commitment to making a difference is unmatched, most recently by helping ensure the retirement security of local teachers, and now in helping Sequence Bio accelerate its search for better, safer medicines and disease treatments. As someone who has built a career on making the smartest investments for the benefit of many, Lynn sees and believes in our global opportunity, and I’m excited for her to play an important role in our continued success.”
Sequence Bio is a Newfoundland and Labrador biotechnology company leading the NL Genome Project to research the unique genetic makeup of our province to discover better, safer medicines and improve how we treat and prevent diseases. We are a committed team of local leaders and international experts driven to make a difference and benefit the lives of Newfoundlanders and Labradorians and others around the world for generations to come.
VP, Market Development